Mechanisms and Treatment of Type 2 High and Low Asthma Endotypes
Clinical & Experimental Allergy · 2025-09 · 55 (9) · 773-783
DOI: 10.1111/cea.70084 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical & Experimental Allergy, online erschienen am 03.06.2025. Verfasst von Timothy C Chin-See-Chong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Asthma, Desensitization, Immunologic, Anti-Asthmatic Agents. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 96 Literaturangaben.
Abstract (Originalsprache)
Asthma is a complex, heterogeneous disease characterised by clinical phenotypes demonstrating distinct and overlapping immunological mechanisms, classified into type‐2 high and type‐2 low asthma endotypes. Both allergic and eosinophilic non‐allergic asthma are driven through an underlying type‐2 high‐endotype, which can be targeted using therapeutic approaches such as allergen‐specific immunotherapy (AIT) for allergic asthma and biologics. AIT demonstrates efficacy for the treatment of allergic asthma. Approved biologics for asthma management include using various interleukin antagonists and anti‐immunoglobulin E, with Tezepelumab offering promising treatments for both type‐2 high and type‐2 low asthma patients. Novel therapeutic candidates, such as Itepekimab and depemokimab, have demonstrated promising results in a Phase 2 clinical trial in moderate‐to‐severe asthma patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary Medicine, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands.
- National Heart and Lung Institute, Imperial College London, London, UK.
- Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK.
- Department of Pulmonary Diseases, Erasmus Medical Centrum, Rotterdam, the Netherlands.
ORCID-Profile: Janice A Layhadi, Johanna P M van der Valk
Zitieren
APA
Chin-See-Chong, T. C., Kappen, J. H., Palmer, E., Layhadi, J. A., Shamji, M. H., & van der Valk, J. P. M. (2025). Mechanisms and Treatment of Type 2 High and Low Asthma Endotypes. Clinical & Experimental Allergy, 55(9), 773-783. https://doi.org/10.1111/cea.70084
Vancouver
Chin-See-Chong TC, Kappen JH, Palmer E, Layhadi JA, Shamji MH, van der Valk JPM. Mechanisms and Treatment of Type 2 High and Low Asthma Endotypes. Clinical & Experimental Allergy. 2025;55(9):773-783. doi:10.1111/cea.70084
BibTeX
@article{ChinSeeChong2025,
author = {Chin-See-Chong, Timothy C and Kappen, Jasper H and Palmer, Elizabeth and Layhadi, Janice A and Shamji, Mohamed H and van der Valk, Johanna P M},
title = {Mechanisms and Treatment of Type 2 High and Low Asthma Endotypes},
journal = {Clinical & Experimental Allergy},
year = {2025},
volume = {55},
number = {9},
pages = {773--783},
doi = {10.1111/cea.70084}
}
EUVIMED